Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma

Journal of Translational Medicine

Volumn 3, Issue , 2005, Pages

  Kawaguchi, Satoshi ^a   Wada, Takuro ^a   Ida, Kazunori ^a   Sato, Yuriko ^a   Nagoya, Satoshi ^a   Tsukahara, Tomohide ^a   Kimura, Sigeharu ^a   Sahara, Hiroeki ^a   Ikeda, Hideyuki ^a   Shimozawa, Kumiko ^b   Asanuma, Hiroko ^a   Torigoe, Toshihiko ^a   Hiraga, Hiroaki ^c   Ishii, Takeshi ^d   Tatezaki, Shin ichiro ^d   Sato, Noriyuki ^a   Yamashita, Toshihiko ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d CHIBA CANCER CENTER   (Japan)

Author keywords

Antigenic peptide; Phase I trial; Synovial sarcoma; SYT SSX; Vaccination

Indexed keywords

CANCER VACCINE; HLA A ANTIGEN; SYT SSX B PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; IN VIVO STUDY; LUNG METASTASIS; MALE; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYNOVIAL SARCOMA;

EID: 18044375060     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-3-1     Document Type: Article

References (19)

1. Fisher C, de Bruijn DR, Geurts van Kessel A: Synovial sarcoma. In World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone Edited by: Fletcher CDM, Unni KK, Mertens F. Lyon: IARC press; 2002:200-204.
2. Deshmukh R, Mankin HJ, Singer S: Synovial sarcoma: the importance of size and location for survival. Clin Orthop 2004:155-161.
3. Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, Somerhausen Nde S, Michels JJ, Jundt G, Vince DR, Taylor S, Genevay M, Collin F, Trassard M, Coindre JM: Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004, 22:4040-4050. Epub 2004 Sep 4013
4. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JS, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B, Larsson O: Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002, 62:135-140.
5. Okcu MF, Munsell M, Treuner J, Mattke A, Pappo A, Cain A, Ferrari A, Casanova M, Ozkan A, Raney B: Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol 2003, 21:1602-1611.
6. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D: Part I: Vaccines for solid tumours. Lancet Oncol 2004, 5: 681-689.
7. Ribas A, Butterfield LH, Glaspy JA, Economou JS: Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003, 21:2415-2432.
8. Ayyoub M, Taub RN, Keohan ML, Hesdorffer M, Metthez G, Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS, Valmori D: The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004, 4: 7.
9. Bennicelli JL, Barr FG: Chromosomal translocations and sarcomas. Curr Opin Oncol 2002, 14:412-419.
10. Rabbitts TH, Stocks MR: Chromosomal translocation products engender new intracellular therapeutic technologies. Nat Med 2003, 9:383-386.
11. Maki RG: Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Curr Opin Oncol 2001, 13:270-274.
12. Le Poole IC, Gerberi T, Kast WM: Emerging strategies in tumor vaccines. Curr Opin Oncol 2002, 14:641-648.
13. Sato Y, Nabeta Y, Tsukahara T, Hirohashi Y, Syunsui R, Maeda A, Sahara H, Ikeda H, Torigoe T, Ichimiya S, Wada T, Yamashita T, Hiraga H, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Umeda T, Ishii S, Kawaguchi S, Sato N: Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol 2002, 169:1611-1618.
14. Ida K, Kawaguchi S, Sato Y, Tsukahara T, Nabeta Y, Sahara H, Ikeda H, Torigoe T, Ichimiya S, Kamiguchi K, Wada T, Nagoya S, Hiraga H, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Ozaki T, Yoshikawa H, Yamashita T, Sato N: Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol 2004, 173:1436-1443.
15. Sato Y, Sahara H, Tsukahara T, Kondo M, Hirohashi Y, Nabeta Y, Kawaguchi S, Ikeda H, Torigoe T, Ichimiya S, Tamura Y, Wada T, Yamashita T, Goto M, Takasu H, Sato N: Improved generation of HLA class I/peptide tetramers. J Immunol Methods 2002, 271: 177-184.
16. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano, Lai L, Jimenez J, Kolitz J, Scheinberg DA: Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000, 95:1781-1787.
17. Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL: Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002, 38:158-164.
18. Matsuzaki A, Suminoe A, Hattori H, Hoshina T, Hara T: Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediatr Hematol Oncol 2002, 24:220-223.
19. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.